Stratifying esophago-gastric cancer treatment using a patient-derived organoid-based threshold.

ABSTRACT:

Background and aims

This study sought to determine the value of patient-derived organoids (PDOs) from esophago-gastric adenocarcinoma (EGC) for response prediction to neoadjuvant chemotherapy (neoCTx).

Methods

Endoscopic biopsies of patients with locally advanced EGC (n = 120) were taken into culture and PDOs expanded. PDOs' response towards the single substances of the FLOT regimen and the combination treatment were correlated to patients' pathological response using tumor regression grading. A classifier based on FLOT response of PDOs was established in an exploratory cohort (n = 13) and subsequently confirmed in an independent validation cohort (n = 13).

Results

EGC PDOs reflected patients' diverse responses to single chemotherapeutics and the combination regimen F

SUBMITTER: Schmache T 

PROVIDER: S-EPMC10777586 | biostudies-literature | 2024 Jan

REPOSITORIES: biostudies-literature